Compare News Corporation Class A Common Stock (NWSA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

News Corporation (NWSA) trades at $29.63, up 0.85% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.20. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.35 surpassing the $0.21 expectation. Revenue for 2025 reached $8.45 billion, though net income is projected to decline significantly in 2026. Recent news highlights include the launch of a personalized news AI, 'Hamilton,' and ongoing speculation about a potential re-merger with Fox Corp.

The outlook is cautiously optimistic, supported by strong analyst sentiment and consistent earnings beats. Key opportunities lie in digital real estate and news monetization, while risks include a projected profit margin contraction and broader market volatility. The stock's current valuation, with a P/E of 28.77, suggests growth expectations are already priced in, requiring sustained execution to justify further upside.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.